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AbsTrACT
background Glaucoma referral filtering schemes have 
operated in the UK for many years. However, there is a 
paucity of data on the false-negative (FN) rate. This study 
evaluated the clinical effectiveness of the Manchester 
Glaucoma Enhanced Referral Scheme (GERS), estimating 
both the false-positive (FP) and FN rates.
Method Outcome data were collected for patients 
newly referred through GERS and assessed in ’usual-
care’ clinics to determine the FP rate (referred patients 
subsequently discharged at their first visit). For the FN 
rate, glaucoma suspects deemed not requiring referral 
following GERS assessment were invited to attend for a 
’reference standard’ examination including all elements 
of assessment recommended by National Institute 
for Health and Care Excellence (NICE) by a glaucoma 
specialist optometrist. A separate 33 cases comprising 
randomly selected referred and non-referred cases were 
reviewed independently by two glaucoma specialist 
consultant ophthalmologists to validate the reference 
standard assessment.
results 1404 patients were evaluated in GERS during 
the study period; 651 (46.3%) were referred to the 
Hospital Eye Service (HES) and 753 (53.6%) were 
discharged. The FP rate in 307 assessable patients 
referred to the HES was 15.5%. This study reviewed 
131 (17.4%) of those patients not referred to the HES 
through the GERS scheme; 117 (89.3%) were confirmed 
as not requiring hospital follow-up; 14 (10.7%) required 
follow-up, including 5 (3.8%) offered treatment. Only 
one patient (0.8%) in this sample met the GERS referral 
criteria and was not referred (true FN). There were 
no cases of missed glaucoma or non-glaucomatous 
pathology identified within our sample.
Conclusion The Manchester GERS is an effective 
glaucoma filtering scheme with a low FP and FN rate.
bACkground
Community optometrists identify ~95% of suspect 
glaucoma and ocular hypertension (OHT) cases 
in the UK through General Ophthalmic Services 
(GOS) sight testing.1 Without ‘filtering’ the 
false-positive (FP) rate for suspect glaucoma refer-
rals is high (~40%).2 3 Glaucoma referral filtering 
schemes have been in operation in the UK for 
more than a decade, and Manchester Glaucoma 
Referral Refinement Scheme (GRRS), now termed 
Glaucoma Enhanced Referral Scheme (GERS),i was 
the first such scheme to be established.4 An early 
evaluation of the Manchester scheme observed 
a reduction in FP rate from ~40% to~10%; 
however, the false-negative (FN) rate was not eval-
uated. Indeed, there is a paucity of data on FN rates 
within community referral filtering schemes.4–6 
One study7 included a retrospective analysis of 100 
sets of notes and optic nerve images of patients not 
referred through the scheme. The authors quoted 
a 3%–10% FN rate and concluded there was ‘no 
compromise on patient safety’.7 Ratnarajan et 
al8 included consultant clinical review of non-re-
ferred patients, although on a limited sample 
of 34 discharged subjects willing to attend the 
hospital for review, and concluded the FN rate 
of optometrists was 15%, although no cases of 
glaucoma were missed. We aimed to evaluate the 
clinical effectiveness of the Manchester GERS by 
estimating both the FP and FN rates. Companion 
qualitative work including the establishment and 
running of the Manchester GERS has previously 
been published.9 10 This paper is the first to report 
on the revised GERS’s clinical effectiveness and 
includes prospective evaluation of a relatively large 
sample of both referred and non-referred subjects.
MeThod
A favourable ethical opinion was granted by 
the National Research Ethics Service (NRES) 
Committee North West (IRAS reference 128578, 
REC reference 14/NW/0024) and added to the 
National Institute for Health Research (NIHR) 
portfolio with Manchester University NHS Foun-
dation Trust as sponsor.
Manchester gers pathway and patient 
recruitment for the false-negative study
The Manchester glaucoma referral pathway is 
summarised in figure 1. All Manchester patients 
identified by their optometrist as a glaucoma suspect 
requiring referral should be directed to GERS for 
i In accordance with recent guidance (including National 
Institute for Health and Care Excellence), practitioners 
providing GRRS should be qualified to make a diagnosis 
of ocular hypertension and suspected glaucoma, and to 
carry out gonioscopy to exclude angle-closure glaucoma, 
whereas Glaucoma Enhanced Referral Scheme does not 
need to include gonioscopy or tests sufficient for a diag-
nosis. The scheme’s name was changed to align with these 
guidelines.
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Figure 1 Manchester pathways for non-GERS (A) and GERS ((B) for patients identified as glaucoma suspects following a routine primary care eye 
examination. GERS, Glaucoma Enhanced Referral Scheme; GP, general practitioner.
referral filtering, unless emergency referral is required. The 
GERS criteria for onward HES referral are summarised in online 
supplementary appendix 1. Although the 2009 National Insti-
tute for Health and Care Excellence (NICE) treatment recom-
mendation11 was not a referral recommendation, this guideline 
was used as a basis for GERS referral guidelines encompassing 
age, intraocular pressure (IOP) and central corneal thickness 
(CCT), facilitating alignment to risk profiles. Following GERS 
assessment, patients are directly referred to the HES glaucoma 
service, discharged to community optometry care or referred to 
the HES via a GOS 18 referral form where non-glaucomatous 
pathology is identified.
Recruitment to the study ran from October 2014 to August 
2016. If an optometrist identified possible glaucoma following 
a routine sight test in Manchester, their patient was referred 
to a GERS-accredited optometrist for evaluation. The GERS 
optometrist, postexamination, either made a direct referral to 
Manchester Royal Eye Hospital (MREH) for specialist assess-
ment or discharged the patient from the scheme.
In order to evaluate the FN rate, 15 accredited GERS clinicians 
(14 optometrists and 1 ophthalmologist) were asked to provide 
all glaucoma suspects deemed to not require referral following 
examination with a patient information sheet informing them 
of the study and explaining that although their examination 
was satisfactory (and that in the opinion of the optometrist the 
patient had no need for further assessment), the hospital has 
invited them to participate in a study evaluating GERS. If the 
patient expressed unwillingness to be contacted, a form was 
completed to confirm their decision. For patients agreeing to be 
contacted, their details were passed to the research team via a 
contact request form. Adult patients ≥18 years of age consenting 
to participate and who post-GERS assessment were deemed to 
not require referral were eligible for inclusion. We excluded chil-
dren, those unable to communicate in English and other patients 
unable to provide fully informed consent. All non-referred 
patients willing to attend MREH for assessment were contacted 
via telephone to offer a ‘reference standard’ examination at a 
research clinic.
hospital research clinic ‘reference standard’ examination
To define an FN within GERS, a reference standard was required, 
and this assessment comprised all standard tests and examinations 
undertaken for a newly referred patient with suspect glaucoma. 
Reference examinations took place in hospital clinics under-
taken by three experienced glaucoma specialist optometrists (ie, 
working in glaucoma specialist clinics for over 10 years) holding 
both the College of Optometrists’ Diploma in Glaucoma and 
Independent Prescribing qualifications. All three optometrists 
work both independently and also alongside consultant ophthal-
mologists in specialist glaucoma clinics. A comprehensive new 
patient examination was performed, including all elements of 
assessment recommended by NICE.11 Assessments in both GERS 
and hospital reference examination included: symptoms and 
history; general health and medications; previous eye history; 
family history; evaluation of glaucoma risk factors; visual acuities; 
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anterior segment assessment; van Herick assessment; Goldmann 
tonometry; pachymetry; visual field assessment; and a dilated 
fundus examination incorporating clinical optic disc assessment 
using slit-lamp biomicroscopy (with either a 78D, 60D or 66D 
lens). The hospital reference standard examination also included 
gonioscopy, and a technician obtained colour optic disc photo-
graphs and OCT RNFL imaging. The care pathway for patients 
attending the reference standard study clinic was aligned to the 
remit of usual MREH care, and patients not requiring follow-up 
were discharged. More specifically, if glaucoma, OHT or suspected 
glaucoma (or any comorbidity) necessitated treatment or hospital 
review, treatment would be initiated if appropriate and a referral 
made to the relevant hospital clinic for follow-up.
Categorisation of patients
The HES optometrist reviewed clinical assessment data and 
classified patients into diagnostic groups: normal (or suspect 
where no HES follow-up needed), OHT, glaucoma suspect or 
glaucoma. Non-glaucomatous ocular comorbidities were noted, 
and appropriate advice, treatment and/or referral were arranged. 
An FN case was deemed to be a case of missed glaucoma (or 
any other comorbidity necessitating HES referral) or a glaucoma 
suspect or OHT case where GERS criteria for referral were trig-
gered on reference standard examination. Specifically, we used 
IOP, visual fields, optic nerve head status and anterior chamber 
angle status by van Herick assessment. Parameters were assessed 
for adherence to single or combined GERS referral criteria 
(online supplementary appendix 1). A final FN classification was 
assigned to each participant as follows:
 ► Unlikely: no evidence from any element of reference 
standard assessment of suspicion of glaucoma or OHT 
necessitating hospital review. Patients falling into this group 
did not, on reference standard assessment, meet any GERS 
referral criterion.
 ► Possible: some element of assessment (eg, IOP, visual fields 
and optic disc status) provided evidence of possible require-
ment for review but potentially a requirement that may not 
have been met on community GERS examination (eg, due to 
variation in IOP).
 ► Likely: much clearer evidence of a requirement at GERS 
examination for the participant to have required referral (eg, 
optic disc examination shows abnormality and confirmed 
visual field loss consistent with glaucoma).
Validation study
To assess the validity of reference standard examination by 
glaucoma specialist optometrists, 33 cases (comprising 30 
randomly selected non-referred cases reviewed in the FN study 
supplemented by three GERS referred cases) were reviewed 
independently by two glaucoma specialist consultant ophthal-
mologists. Here, data from the clinical episode including history 
and symptoms, IOP, CCT, anterior segment assessment including 
van Herick’s grading, gonioscopy, visual field assessment and 
stereoscopic optic disc images were presented. The research 
optometrists’ decision making was masked, and the consultants 
were categorised patients into the same diagnostic groupings, 
that is, normal (or suspect where no HES follow-up needed), 
OHT, glaucoma suspect or glaucoma. They were also asked, 
according to GERS criteria, whether they would have discharged 
the patient or referred them to the HES.
False positives
Outcome data were collected for patients newly referred through 
GERS during the timeline of the study and assessed in usual care 
glaucoma clinics. In the absence of an electronic patient record, 
all outcome data were manually retrieved from the case notes, 
whereby clinicians were asked to retain patients’ records after 
clinics for GERS referred patients seen in HES new patient glau-
coma clinics. Patients examined and subsequently discharged at 
their first visit were defined as FP cases for the purpose of this 
study.
resulTs
recruitment
There were 1404 patients evaluated in GERS during the study 
period. The flow chart for patients seen in the scheme and study 
during this period is detailed in figure 2, facilitating assessment 
of risk of bias.12
False-positive study
For patients referred from the GERS and examined, we managed 
to retain case records for 307 patients and review the outcomes 
of the 283 patients who attended, as detailed in table 1.
False-negative study
The overall return rate for contact request forms was 40.9%, 
although there was a large variation in return rate between 
community optometry practices (median (IQR) between prac-
tices 50 (15-67)%, p<0.001, χ2 test) with seemingly differen-
tial compliance with study recruitment requirements. Only one 
practitioner failed to return any forms, potentially relating to 
low overall activity in GERS, seeing just eight patients over the 
study period. The 72.1% consent rate in agreement to partic-
ipate was, however, more consistent within forms returned 
from practices (median (IQR) between practices 75 (67-88)%, 
p=0.034), although there was still a statistically significant 
difference between practices. The mean time lag from GERS 
assessment to reference standard examination was~6.5 weeks 
(45.0 days, SD 38.7, range 3–208 days).
Fn rate
The vast majority of patients were subsequently discharged at 
their HES study visit (N=117, 89.3%). The outcomes for those 
assessed in the FN study are summarised in table 2.
Fisher’s exact test shows there was no significant difference 
between practices in the overall FN rate (HES vs discharge), 
p=0.27. Within our FN study sample evaluated in the HES, 
there were no incidents of missed non-glaucomatous pathology 
requiring referral post-GERS assessment.
Validation study
When comparing consultant to consultant decision making, 
there was agreement between consultants on management deci-
sions in 23 of 30 non-referred cases versus 25 of 30 and 24 of 30 
cases where the glaucoma specialist optometrist and each indi-
vidual consultant were in agreement. This finding suggests that 
the glaucoma specialist optometrists’ decision making demon-
strated non-inferiority when compared with consultant–consul-
tant agreement. There were only two cases (7%) where both 
consultants agreed, and their decision was different to that of 
the specialist optometrists’ decision, and in each case, the consul-
tant would have discharged the patient, whereas the glaucoma 
specialist optometrist considered HES follow-up or treatment 
was required.
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Figure 2 Patient flow chart for recruitment of patients. GERS, Glaucoma Enhanced Referral Scheme.
disCussion
A range of glaucoma filtering schemes has been developed in 
the UK with the aim to improve accuracy of referrals to the 
HES,4 6 7 including repeat measures, enhanced case findin-
gand referral refinement schemes. The aim of this service is to 
provide a safe and efficient pathway for patients to be reviewed 
promptly after referral for suspect glaucoma, closer to home, 
by accredited optometrists, while reducing the FP referral rate 
to the HES. A previous evaluation has shown the FP rate to 
reduce from ~40% to ~10%.4 A subsequent study comparing 
a number of ‘referral refinement’ schemes demonstrated 
that specialist-trained optometrists can reduce the first visit 
discharge rate of patients subsequently reviewed in secondary 
care compared with direct referrals from non-specialist optom-
etrists by 22%.5
In the present study, there was a low referral rate to the HES, 
with 53.6% patients being discharged following GERS commu-
nity assessment, thereby potentially providing a financial saving 
to the NHS.The FP rate within the scheme was found to be 
15.5%, much lower than that found in Ratnarajan et al’s5 study 
looking at referrals from non-specialist optometrists to the HES, 
where the mean FP rate was up to 43.9%.Indeed, another study 
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Table 1 Outcomes of patients referred through GERS for MREH 
glaucoma assessment and where the outcome is known
n % (95% Ci) 
Monitor without 
treatment 
153/283
  
54.1 (47.9 to 59.4)%
  OHT 18 11.8%
  PACS 13 8.5%
  Suspect 122 79.7%
Monitor with treatment 78/283
 
27.6 (22.6 to 33.0)% 
  Glaucoma 42 53.8%
  OHT 13 16.7%
  PAC/S 13 24.4%
  Suspect 4 5.1%
Further investigations 
required (eg, day phasing) 
9/283 3.2 (1.7 to 5.9)%
  Glaucoma 3 33.3%
  Suspect 6 66.7%
Did not attend 24/307 7.8%
Discharge 44/283 15.5 (11.8 to 20.2)%
There was no significant difference (p=0.31, χ2 test) across optometric practices 
when comparing the FP rate. Percentages with exact binomial CIs exclude non-
attenders.
GERS, Glaucoma Enhanced Referral Scheme;MREH, Manchester Royal Eye 
Hospital;OHT, ocular hypertension;PAC, primary angle closure;PAC/S, primary angle 
closure suspect.
Table 2 Classification of patients seen in the FN study using the protocol definitions
n % (95% Ci) n % (95% Ci) 
Glaucoma unlikely (did not meet referral criteria at GERS or require 
follow-up)
117 89.3 (82.9 to 
93.5)% 
Glaucoma possible (did not meet referral criteria at GERS, but required 
follow-up) 
13 9.9 (5.9 to 16.2)% Treated 
 
5 3.8 (1.6 to 8.6)%
OHT treated with drops
3 60.0%
PACS treated with laser 2 40.0%
Untreated 8 6.1 (3.1 to 11.6)%
OHT/glaucoma suspect 4 50.0%
PACS 4 50.0%
Glaucoma likely (did meet referral criteria at GERS but was not referred) 1 0.8 (0 to 4.2)% Treated 0 0 (0.0 to 2.8)%
Untreated 1 8.0 (0.0 to 4.2)% 
Glaucoma suspect 1 100%
Overall FN 14 10.7 (6.4 to 17.1)% Treated 5 3.8 (1.6 to 8.6)% 
Untreated 9 6.9 (3.7 to 12.5)% 
FN, false negative;GERS, Glaucoma Enhanced Referral Scheme;OHT, ocular hypertension;PACS, primary angle closure suspect.
showed the positive predictive value of referrals to be as low as 
25%.13
Some previous research has examined the FN rate in referral 
filtering schemes, with the Carmarthenshire study showing an 
FN rate of 3%–10%.7 There are, however, difficulties associ-
ated with estimating the FN rate from retrospective review of 
case notes and optic disc photos, including the possibility that 
other ocular parameters may have been abnormal (eg, status of 
the anterior chamber angle). A recent prospective study looking 
at 82 patients seen in the Moorfields ‘virtual triage’ scheme 
showed an FN rate of 4%–20%, dependent on FN definition.14 
The FN rate in Ratnarajan et al’s study8 was 15%; however, only 
a limited number of patients were examined in their study, and 
the results were assessed virtually. Our study is therefore the 
largest prospective FN study within a glaucoma filtering scheme, 
and uniquely the assessment of patients replicated usual care for 
referred patients, encompassing all NICE recommended investi-
gations sufficient for diagnosis.
Only one patient meeting GERS criteria for referral was not 
actually referred. The GERS optometrist labelled visual fields as 
‘normal’ on the GERS assessment pro forma, despite the attached 
visual field plot showing field changes where glaucoma could 
not be excluded. Reference standard examination indicated 
no definite glaucoma but deemed requirement for HES moni-
toring without treatment (ie, a chronic open angle glaucoma 
suspect). This single case indicates an FN rate of 0.8%, with 95% 
CI excluding values above 4.2%, where an FN is defined as a 
patient who was not referred but who ought to triggered referral 
at the point of GERS assessment. Following additional assess-
ment a further 13 patients (9.9%) were followed up, 5 of whom 
(3.8%) received prophylactic treatment with topical medication 
or laser. Three of these five patients (2.3% of patients seen in 
the study) were patients diagnosed with OHT, but none had 
IOPs meeting the referral threshold at GERS assessment. There 
were no patients with narrow angles and raised IOPs deemed 
to require both medical and laser treatment. The discrepancy 
in IOP measurement between GERS and reviewer consultations 
may be explained by many factors, including interobserver and/
or diurnal variation in IOP measurements.15 The remaining two 
treated patients (1.5%) had asymptomatic narrow angles who 
met the European Glaucoma Society Guidelines’ recommenda-
tion for treatment with YAG laser peripheral iridotomy.16 Both 
patients had a van Herick assessment of grade 1 in each eye but 
did not meet the then GERS referral criteria, since they were 
both asymptomatic. The remaining eight patients followed up 
without treatment either had narrow angles not requiring treat-
ment but judged to benefit from monitoring (N=4, 3.1%) or 
labelled as glaucoma suspects (N=4, 3.1%) in accordance with 
NICE definitions.11 The one patient not referred, but actually 
meeting the referral criteria at the point of GERS, did not require 
treatment at follow-up, indicating there were no incidents of 
missed glaucoma requiring treatment within our study sample.
One potential limitation of the current research is the failure 
to secure outcome data on all patients seen within the HES 
following GERS referral. In the absence of an electronic patient 
record, data retrieval relied on clinicians to retain notes after 
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clinic. The outcome data for those where patients’ notes could 
be reviewed is, however, comparable with an earlier analysis of 
the then GRRS scheme.4 All patients examined and subsequently 
discharged at their first visit were defined as FP cases for the 
purpose of this study. However, a proportion of these cases might 
arguably have been reasonably referred in, necessitating decision 
making by a more specialist clinician. A further limitation is argu-
ably the use of experienced glaucoma specialist optometrists to 
provide the hospital-based reference standard assessment versus 
specialist glaucoma consultants. However, set against this poten-
tial limitation is the optometrists’ apparent caution in assessment 
in the validation study. While this validation study is limited in 
not affording consultants with an opportunity for direct patient 
examination (including gonioscopy) and they relied on the avail-
able reference standard examination findings, they did review 
subjects’ optic disc and visual field status. The optometrist had 
the same judgement in all cases where either consultant would 
refer plus an additional two (7%) cases, and the FN rate would 
not be expected to be underestimated compared with consultant 
assessment. Agreement in glaucoma management between glau-
coma specialist optometrists and glaucoma specialist consultant 
ophthalmologists has been studied in the past, demonstrating 
good agreement in our study centre.17 Apparent disagreement 
between glaucoma specialists highlights the subjective nature of 
glaucoma assessment and the impossibility of a perfect referral 
filtering scheme, given measurement imprecision and the impli-
cations of balancing sensitivity and specificity in referral criteria. 
A further limitation is that of the delay (mean of~6.5 weeks) 
in HES reference standard assessment following community 
GERS examination, with possibility for real change in status in a 
minority of subjects included in our evaluation.
Reflecting on the results of this study, as well as on feedback 
from GERS accredited optometrists,10 GERS referral criteria 
have since been modified to specify that any patient with a van 
Herick grade 1 may be referred through GERS, regardless of 
symptoms. Following publication of updated NICE guidance,18 
GERS referral criteria are being revised, taking into consider-
ation referral criteria within the updated guideline, and these 
changes could potentially alter the outcomes. For example, in 
the present FN study sample, had an IOP criterion of ≥24 mm 
Hg been the referral threshold, nine referrals would have been 
made.
It is clear that GERS is highly successful in reducing the FP 
rate from community referrals for suspect glaucoma. The FN 
evaluation in this study shows that GERS is clinically effective 
and very safe, offering reassurance to commissioners wishing to 
implement community pathways.
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